AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17022378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily for 4 weeks)
Number of subjects: 30
Study 17022378 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment during the observation period)
Number of subjects: 30
Study 14672470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours, followed by one additional scheduled dose postpartum (study group)
Number of subjects: 292
Study 14672470 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours, continued until afebrile and asymptomatic for 24 hours (control group)
Number of subjects: 292
Study 10723818 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 0
Study 10723818 — intervention group
Group type: COMPARATOR
Intervention: Nicotine oral inhaler
Number of subjects: 0
Study 10723818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination NRT
Number of subjects: 0
Study 9369626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressing (N = 49)
Number of subjects: 80
Study 9369626 — intervention group
Group type: COMPARATOR
Intervention: Sterile gauze dressing (N = 31)
Number of subjects: 80
Study 31407970 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 99
Study 31407970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 30562083 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB) angioplasty
Number of subjects: 263
Study 30562083 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty
Number of subjects: 263
Study 26689885 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin 5000 units three-times a day
Number of subjects: 50
Study 26689885 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of unfractionated heparin 625 IU/h
Number of subjects: 50
Study 25076007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 77
Study 25076007 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 77
Study 22525915 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (2 mL 1% buffered lidocaine at tenaculum site + 18 mL at four sites)
Number of subjects: 120
Study 22525915 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 120
Study 22525915 — intervention group
Group type: COMPARATOR
Intervention: Sham (no injection)
Number of subjects: 120
Study 18377682 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS (10 g once daily for 5 weeks)
Number of subjects: 20
Study 18377682 — intervention group
Group type: EXPERIMENTAL
Intervention: BLEND (50% FOS and 50% acacia gum; 10 g once daily for 5 weeks)
Number of subjects: 20
Study 18377682 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (10 g once daily for 2 weeks during run-in phase)
Number of subjects: 20
Study 18377682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported general wellbeing
Number of subjects: 20
Study 16488689 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated oxygenator
Number of subjects: 39
Study 16488689 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygenator (control group)
Number of subjects: 39
Study 14708414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (2 mg/kg)
Number of subjects: 20
Study 14708414 — intervention group
Group type: COMPARATOR
Intervention: 5% tramadol (2 mg/kg)
Number of subjects: 20
Study 14708414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg/kg) administered rectally if pain score > 3/10
Number of subjects: 20
Study 10976598 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrastive properties (1 transparent and 1 opaque object)
Number of subjects: 2
Study 10976598 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent properties (2 transparent objects)
Number of subjects: 2
Study 9291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (INTEGRILIN)
Number of subjects: 0
Study 9291242 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8325058 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 14
Study 3552358 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 +/- 20 mg/day)
Number of subjects: 8
Study 3552358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3552358 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (450 +/- 30 mg/day)
Number of subjects: 8
Study 29401192 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient preworkout supplement (SUP)
Number of subjects: 12
Study 26614506 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3 (‐)‐rich beetroot juice (BR; 8.2 mmol NO3‐ day(‐1))
Number of subjects: 10
Study 26614506 — intervention group
Group type: COMPARATOR
Intervention: NO3 (‐)‐depleted beetroot juice (PL; 0.08 mmol NO3‐ day(‐1))
Number of subjects: 10
Study 24272064 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz method
Number of subjects: 0
Study 24272064 — intervention group
Group type: COMPARATOR
Intervention: Ether-concentration technique
Number of subjects: 0
Study 22997217 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise training
Number of subjects: 53
Study 22997217 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise training
Number of subjects: 53
Study 22997217 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 53
Study 20718396 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program for clinicians to support patients making decisions about place of end-of-life care
Number of subjects: 88
Study 20718396 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 88
Study 18788218 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy (minimal extracorporeal circulation system)
Number of subjects: 20
Study 18788218 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 20
Study 16827017 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 120
Study 16827017 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium hydroxide liner (Life)
Number of subjects: 120
Study 16827017 — intervention group
Group type: EXPERIMENTAL
Intervention: cavity varnish (Copalite)
Number of subjects: 120
Study 16827017 — intervention group
Group type: EXPERIMENTAL
Intervention: resin modified glass ionomer liner (Vitrebond)
Number of subjects: 120
Study 16827017 — intervention group
Group type: EXPERIMENTAL
Intervention: dentin adhesive resin liner (Single Bond)
Number of subjects: 120
Study 16827017 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorhexidine disinfectant (Consepsis)
Number of subjects: 120
Study 12926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utility Index (HUI)
Number of subjects: 80
Study 12926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 80
Study 12926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scales
Number of subjects: 80
Study 12926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional health status measures (CHAQ, ASK)
Number of subjects: 80
Study 12926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental ratings
Number of subjects: 80
Study 10997806 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 plus carboplatin 6 AUC (group A)
Number of subjects: 198
Study 10997806 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 225 mg/m2 plus carboplatin 6 AUC (group B)
Number of subjects: 198
Study 9144347 — intervention group
Group type: EXPERIMENTAL
Intervention: TIB, tibolone, 2.5 mg/day continuously, orally
Number of subjects: 140
Study 9144347 — intervention group
Group type: EXPERIMENTAL
Intervention: PO, peroral E2, 2 mg/day continuously, plus sequential oral dydrogesterone (DYD), 10 mg/day, for 14 days of a 28-day cycle
Number of subjects: 140
Study 9144347 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS, transdermal E2 by patch releasing 50 microg/day, plus DYD as above
Number of subjects: 140
Study 9144347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 140
Study 1388338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg)
Number of subjects: 136
Study 1388338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine (6 mg)
Number of subjects: 136
Study 1388338 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms, control group)
Number of subjects: 136
Study 3979761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure diet preparation for 48 hours
Number of subjects: 72
Study 3979761 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet preparation for 48 hours
Number of subjects: 72
Study 3979761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure with two consecutive evenings of laxatives without enemas
Number of subjects: 72
Study 3979761 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet with evening-laxative and morning-enema regimen
Number of subjects: 72
Study 29661229 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mm Exeter V40 stem
Number of subjects: 220
Study 29661229 — intervention group
Group type: COMPARATOR
Intervention: 150 mm Exeter V40 stem
Number of subjects: 220
Study 28668422 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MBIR)
Number of subjects: 89
Study 28668422 — intervention group
Group type: COMPARATOR
Intervention: Adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 89
Study 28668422 — intervention group
Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 89
Study 25523287 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0888 (VEGFR-2 inhibitor) at doses up to 100 mg in healthy volunteers; pharmacokinetics and safety evaluated.
Number of subjects: 0
Study 25523287 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0888 (VEGFR-2 inhibitor) at doses of 6-100 mg administered up to twice daily in cancer patients; pharmacokinetics and safety evaluated.
Number of subjects: 0
Study 25523287 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0888 (VEGFR-2 inhibitor) at doses of 50 mg twice daily and higher for multiple-dose administration.
Number of subjects: 0
Study 23688651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpurpuragenic 595-nm pulsed dye laser (PDL)
Number of subjects: 14
Study 23688651 — intervention group
Group type: COMPARATOR
Intervention: Microsecond 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser
Number of subjects: 14
Study 21367884 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF), 30 g daily for two months along with standard drug therapy
Number of subjects: 41
Study 21367884 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 41
Study 21367884 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF)
Number of subjects: 41
Study 18510613 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) measurement in cirrhotic patients with minimal hepatic encephalopathy (HE)
Number of subjects: 64
Study 18510613 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC values of white matter regions (frontal and parietal)
Number of subjects: 64
Study 18510613 — intervention group
Group type: COMPARATOR
Intervention: ADC measurement
Number of subjects: 64
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 2082
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty with abciximab
Number of subjects: 2082
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion (<3 hours)
Number of subjects: 2082
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion in high-risk patients (<3 hours)
Number of subjects: 2082
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion in low-risk patients (<3 hours)
Number of subjects: 2082
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon times in patients presenting early (<2 hours)
Number of subjects: 2082
Study 16781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon times in patients presenting late (>2 hours)
Number of subjects: 2082
Study 14604201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose/7.5% icodextrin
Number of subjects: 11
Study 14604201 — intervention group
Group type: COMPARATOR
Intervention: 1.36% glucose
Number of subjects: 11
Study 14604201 — intervention group
Group type: COMPARATOR
Intervention: 7.5% icodextrin
Number of subjects: 11
Study 14604201 — intervention group
Group type: COMPARATOR
Intervention: 3.86% glucose
Number of subjects: 11
Study 11095449 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2) 1 or 2 mg daily for 3 days
Number of subjects: 59
Study 11095449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11095449 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2)
Number of subjects: 59
Study 9347428 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.49 microgram/kg/min)
Number of subjects: 35
Study 9347428 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (1.99 micrograms/kg/min)
Number of subjects: 35
Study 9347428 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.25 microgram/kg/min)
Number of subjects: 35
Study 9347428 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 35
Study 9347428 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 35
Study 8180725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 54
Study 8180725 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (DT)
Number of subjects: 54
Study 3529151 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 7
Study 3529151 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 30808230 — intervention group
Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 0
Study 30808230 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study 28233343 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized brain fitness exercise
Number of subjects: 0
Study 28233343 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory support system
Number of subjects: 0
Study 28233343 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 28233343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Computerized brain fitness exercise and Memory support system)
Number of subjects: 0
Study 25909969 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule of threes algorithm with oxytocin 3 IU
Number of subjects: 60
Study 25909969 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of oxytocin (30 IU in 0.9% normal saline/500 ml)
Number of subjects: 60
Study 24263699 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic visits
Number of subjects: 175
Study 24263699 — intervention group
Group type: COMPARATOR
Intervention: Home lighting
Number of subjects: 175
Study 20372949 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride application (sodium fluoride)
Number of subjects: 0
Study 20372949 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical enamel treatment with acidulated phosphate fluoride
Number of subjects: 0
Study 20372949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidulate fluoride-free solution
Number of subjects: 0
Study 20372949 — intervention group
Group type: COMPARATOR
Intervention: Professional brushing, ultrasound action, or chemical extraction
Number of subjects: 0
Study 19590159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular endurance training (CVE) for 10 months
Number of subjects: 55
Study 19590159 — intervention group
Group type: COMPARATOR
Intervention: Balance and flexibility training (FLEX) for 10 months
Number of subjects: 55
Study 19590159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CVE and FLEX
Number of subjects: 55
Study 17996126 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2
Number of subjects: 10
Study 17996126 — intervention group
Group type: COMPARATOR
Intervention: RA
Number of subjects: 10
Study 15102146 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated regret when 'nearly won' vs 'clearly lost' a contest
Number of subjects: 0
Study 15102146 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated regret and self-blame when 'nearly caught' vs 'clearly missed' a train
Number of subjects: 0
Study 11238542 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 20
Study 11238542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9574640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin solution (hypervolemia group, n = 19)
Number of subjects: 43
Study 9574640 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution + 5% albumin solution (normovolemia group, n = 24)
Number of subjects: 43
Study 9574640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin solution (hypervolemia group)
Number of subjects: 43
Study 8160445 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovaccines
Number of subjects: 3663
Study 8160445 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivaccine
Number of subjects: 3663
Study 8160445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3663
Study 2971597 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF plus Provera 200 mg daily for 3 weeks followed cyclically by Tamoxifen 20 mg daily for 3 weeks
Number of subjects: 46
Study 2971597 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, 5‐fluorouracil)
Number of subjects: 46
Study 2971597 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclical hormonal therapy
Number of subjects: 46
Study 31869312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 30
Study 31869312 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 30
Study 30077810 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol (5 or 10 μg)
Number of subjects: 0
Study 30077810 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 μg)
Number of subjects: 0
Study 30077810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28550756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICM plus telehealth monitoring
Number of subjects: 51
Study 28550756 — intervention group
Group type: COMPARATOR
Intervention: ICM
Number of subjects: 51
Study 26194648 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal coverage of insecticide-treated nets (ITNs) only
Number of subjects: 300
Study 26194648 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal coverage of insecticide-treated nets (ITNs) combined with high coverage of indoor residual spraying (IRS)
Number of subjects: 300
Study 23183220 — intervention group
Group type: EXPERIMENTAL
Intervention: Right PPC cTBS
Number of subjects: 0
Study 23183220 — intervention group
Group type: EXPERIMENTAL
Intervention: Left DLPFC cTBS
Number of subjects: 0
Study 23183220 — intervention group
Group type: EXPERIMENTAL
Intervention: Right DLPFC cTBS
Number of subjects: 0
Study 23183220 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 0
Study 21971726 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises of the lower extremities at 70% of 1RM, three times/week for ten weeks
Number of subjects: 32
Study 18477161 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment for 4-6 months until a cumulative dose of 120 mg/kg
Number of subjects: 36
Study 18477161 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 16546214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g acamprosate
Number of subjects: 601
Study 16546214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g acamprosate
Number of subjects: 601
Study 16546214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 16546214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g acamprosate (post-hoc analysis)
Number of subjects: 601
Study 16546214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g acamprosate (post-hoc analysis)
Number of subjects: 601
Study 16546214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (post-hoc analysis)
Number of subjects: 601
Study 16546214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g acamprosate (subgroup analysis)
Number of subjects: 601
Study 16546214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g acamprosate (subgroup analysis)
Number of subjects: 601
Study 16546214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup analysis)
Number of subjects: 601
Study 14629775 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative Ergonomics protocol performed by an ergonomist
Number of subjects: 0
Study 14629775 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Activity based on cognitive behavioural principles by a physiotherapist
Number of subjects: 0
Study 14629775 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by an occupational physician according to Dutch guidelines
Number of subjects: 0
Study 12271193 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntleigh Nimbus 3
Number of subjects: 141
Study 12271193 — intervention group
Group type: COMPARATOR
Intervention: Aura Cushion
Number of subjects: 141
Study 12271193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasus Cairwave Therapy System
Number of subjects: 141
Study 12271193 — intervention group
Group type: COMPARATOR
Intervention: ProActive Seating Cushion
Number of subjects: 141
Study 9011895 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron during cardiopulmonary bypass
Number of subjects: 20
Study 9011895 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 20